Lead Product(s) : RXRG001
Therapeutic Area : Dental and Oral Health
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
RiboX Announces First Patient Dosed in Phase I/IIa Clinical Trial of RXRG001
Details : RXRG001 is an AQP1 modulator, circular RNA, which is currently being evaluated for the treatment of patients with radiation-induced-xerostomia (RIX) and hyposalivation.
Product Name : RXRG001
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 09, 2025
Lead Product(s) : RXRG001
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable